Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study

C. la Vecchia, A. Decarli, M. Fasoli, S. Franceschi, A. Gentile, E. Negri, F. Parazzini, G. Tognoni

Research output: Contribution to journalArticle

Abstract

We analysed data from a case-control investigation conducted in Milan, Northern Italy, to evaluate the relationship between the use of combination oral contraceptives and the risk of cancers of the breast, ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast cancer, 406 of epithelial ovarian cancer and 170 of endometrial cancer aged under 60 were compared with a group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225 cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95% confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95% CI = 0.48-0.97) for epithelial ovarian cancer, 0.50 (95% CI = 0.23-1.12) for endometrial cancer, 1.49 (95% CI = 0.88-2.55) for cervical cancer and 0.77 (95% CI = 0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis of sub-groups of age, parity or other potentially important covariates did not show any important interaction, and allowance for them by means of logistic regression did not materially modify any of the results. These data confirm that combination oral contraceptives confer some protection against ovarian and endometrial cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer.

Original languageEnglish
Pages (from-to)311-317
Number of pages7
JournalBritish Journal of Cancer
Volume54
Issue number2
DOIs
Publication statusPublished - 1986

Fingerprint

Mouth Neoplasms
Oral Contraceptives
Case-Control Studies
Uterine Cervical Neoplasms
Breast Neoplasms
Confidence Intervals
Endometrial Neoplasms
Ovarian Neoplasms
Italy
Neoplasms
Endometrium
Parity
Cervix Uteri
Inpatients
Outpatients
Age Groups
Logistic Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

la Vecchia, C., Decarli, A., Fasoli, M., Franceschi, S., Gentile, A., Negri, E., ... Tognoni, G. (1986). Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. British Journal of Cancer, 54(2), 311-317. https://doi.org/10.1038/bjc.1986.178

Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. / la Vecchia, C.; Decarli, A.; Fasoli, M.; Franceschi, S.; Gentile, A.; Negri, E.; Parazzini, F.; Tognoni, G.

In: British Journal of Cancer, Vol. 54, No. 2, 1986, p. 311-317.

Research output: Contribution to journalArticle

la Vecchia, C. ; Decarli, A. ; Fasoli, M. ; Franceschi, S. ; Gentile, A. ; Negri, E. ; Parazzini, F. ; Tognoni, G. / Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. In: British Journal of Cancer. 1986 ; Vol. 54, No. 2. pp. 311-317.
@article{5a6908f50e8841f8b422cf1a41fb06eb,
title = "Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study",
abstract = "We analysed data from a case-control investigation conducted in Milan, Northern Italy, to evaluate the relationship between the use of combination oral contraceptives and the risk of cancers of the breast, ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast cancer, 406 of epithelial ovarian cancer and 170 of endometrial cancer aged under 60 were compared with a group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225 cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95{\%} confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95{\%} CI = 0.48-0.97) for epithelial ovarian cancer, 0.50 (95{\%} CI = 0.23-1.12) for endometrial cancer, 1.49 (95{\%} CI = 0.88-2.55) for cervical cancer and 0.77 (95{\%} CI = 0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis of sub-groups of age, parity or other potentially important covariates did not show any important interaction, and allowance for them by means of logistic regression did not materially modify any of the results. These data confirm that combination oral contraceptives confer some protection against ovarian and endometrial cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer.",
author = "{la Vecchia}, C. and A. Decarli and M. Fasoli and S. Franceschi and A. Gentile and E. Negri and F. Parazzini and G. Tognoni",
year = "1986",
doi = "10.1038/bjc.1986.178",
language = "English",
volume = "54",
pages = "311--317",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study

AU - la Vecchia, C.

AU - Decarli, A.

AU - Fasoli, M.

AU - Franceschi, S.

AU - Gentile, A.

AU - Negri, E.

AU - Parazzini, F.

AU - Tognoni, G.

PY - 1986

Y1 - 1986

N2 - We analysed data from a case-control investigation conducted in Milan, Northern Italy, to evaluate the relationship between the use of combination oral contraceptives and the risk of cancers of the breast, ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast cancer, 406 of epithelial ovarian cancer and 170 of endometrial cancer aged under 60 were compared with a group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225 cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95% confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95% CI = 0.48-0.97) for epithelial ovarian cancer, 0.50 (95% CI = 0.23-1.12) for endometrial cancer, 1.49 (95% CI = 0.88-2.55) for cervical cancer and 0.77 (95% CI = 0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis of sub-groups of age, parity or other potentially important covariates did not show any important interaction, and allowance for them by means of logistic regression did not materially modify any of the results. These data confirm that combination oral contraceptives confer some protection against ovarian and endometrial cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer.

AB - We analysed data from a case-control investigation conducted in Milan, Northern Italy, to evaluate the relationship between the use of combination oral contraceptives and the risk of cancers of the breast, ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast cancer, 406 of epithelial ovarian cancer and 170 of endometrial cancer aged under 60 were compared with a group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225 cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95% confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95% CI = 0.48-0.97) for epithelial ovarian cancer, 0.50 (95% CI = 0.23-1.12) for endometrial cancer, 1.49 (95% CI = 0.88-2.55) for cervical cancer and 0.77 (95% CI = 0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis of sub-groups of age, parity or other potentially important covariates did not show any important interaction, and allowance for them by means of logistic regression did not materially modify any of the results. These data confirm that combination oral contraceptives confer some protection against ovarian and endometrial cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022492561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022492561&partnerID=8YFLogxK

U2 - 10.1038/bjc.1986.178

DO - 10.1038/bjc.1986.178

M3 - Article

C2 - 3741766

AN - SCOPUS:0022492561

VL - 54

SP - 311

EP - 317

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -